

Conference Call on Interim Report 2/2014



Favourable results for the first half of 2014

4.9% increase of Group net income; Shareholders' equity up by 8.9%

Group

► Gross written premium: EUR 7,065 m. (-2.2%)

Net premium earned: EUR 5,839 m. (-5.7%)

▶ EBIT: EUR 684 m.

Group net income: EUR 444 m.

► RoE: 14.5%

► Book value per share: EUR 53.17

Shareholders' equity: EUR 6,412 m.

GWP impacted by currency fluctuations;
 f/x-adjusted growth of +0.4% in line with expectations

 Group net income up by 4.9% fuelled by improved results from life and health

- Book value per share at record high
- ► Earnings and increase in OCI boost shareholders' equity

Non-life R/I

EBIT: EUR 521 m.

- Strong profitability (EBIT margin of 15.5%) driven by favourable underwriting result (C/R of 95.0%)
- Net major losses of only EUR 105 m. (3.1% of NPE)
- Continued selective U/W approach; increased volume from Chinese and South Asian business results in moderate f/x-adjusted growth of 2.0 %

Life and health R/I

EBIT: EUR 155 m.

- Significantly improved operating result (+16%) compared to 1H/2013 in line with our full-year guidance
- ▶ Pleasing EBIT margin of 6.3%
- Good underlying growth masked by reduced premiums from UK enhanced annuities and single large transactions

Investments

NII: EUR 708 m.

- ► Rol of 3.3% above full-year target of 3.2%
- Ordinary investment income within expected range
- ► Change in fair value of investments has almost no impact in 1H/2014



Pleasing underwriting result leads to strong operating profit

Half-year result fully in line with 2014 target


Group figures in m. EUR	Q2/2013	Q2/2014	1H/2013	1H/2014
Gross written premium	3,469	3,440	7,227	7,065
Net premium earned	3,111	2,927	6,192	5,839
Net underwriting result	(15)	12	17	14
- Incl. funds withheld	79	98	204	189
Net investment income	334	346	689	708
- From assets under own mgmt.	241	260	501	533
- From funds withheld	94	86	188	175
Other income and expenses	7	(24)	(13)	(38)
Operating profit/loss (EBIT)	327	334	693	684
Interest on hybrid capital	(32)	(21)	(63)	(49)
Net income before taxes	295	313	630	635
Taxes	(85)	(93)	(172)	(156)
Net income	209	220	458	479
- Non-controlling interests	17	8	35	35
Group net income	192	211	423	444
Retention	90.1%	87.1%	90.0%	87.7%
EBIT margin (EBIT/Net premium earned)	10.5%	11.4%	11.2%	11.7%
Tax ratio	29.0%	29.8%	27.3%	24.5%
Earnings per share	1.59	1.75	3.51	3.69

YTD

- ► GWP f/x-adjusted growth +0.4%
- ▶ NPE f/x-adjusted growth -3.1%
- ➤ Other income and expenses lower due to normalisation of currency effects
- ▶ Reduced interest on hybrid capital due to EUR 750 m. subordinated bond redemption in Q1/2014




Shareholders' equity increased by 8.9%





Continued positive cash flow despite reduced premium growth

Increased AuM despite payments of EUR 1.1 bn. for dividends and bond redemption




Pleasing U/W result in a competitive market environment

Non-life reinsurance in m. EUR	Q2/2013	Q2/2014	1H/2013	1H/2014	YTD
Gross written premium	1,899	1,970	4,097	4,078	► GWP f/x-adjusted growth +2.0%; mainly from Southeast Asia and China
Net premium earned	1,712	1,739	3,404	3,370	▶ NPE f/x-adjusted growth +1.6%
Net underwriting result incl. funds withheld	90	76	191	168	► Major losses of EUR 105 m. (3.1% of NPE) below budget (EUR 276 m. for 1H/2014)
Combined ratio incl. interest on funds withheld	94.8%	95.6%	94.4%	95.0%	 Conservative loss reserving policy maintained in particular for the large loss budget
Net investment income from assets under own management	172	188	355	389	NII increased mainly due to normalised results from inflation swaps
Other income and expenses	29	(24)	2	(36)	➤ Other inc. & exp. in line with expectations; not affected by positive currency effects as in 2013
Operating profit/loss (EBIT)	290	241	549	521	► EBIT margin of 15.5% (1H/2013: 16.1%), well above target
Tax ratio	30.0%	34.6%	28.0%	28.5%	
Group net income	187	150	362	348	
Earnings per share	1.55	1.24	3.00	2.89	



Overall portfolio continues to outperform the MtCR

Costa Concordia takes its toll in marine




MtCR = Maximum tolerable Combined Ratio



^{*} All lines of non-life reinsurance except those stated separately

Major losses below expectation

Remaining large loss budget (EUR 565 m.) provides comfortable cushion for 2H/2014



¹⁾ Up to 2011 claims over EUR 5 m. gross, from 2012 onwards claims over EUR 10 m. gross



^{2) 2004 - 2006} adjusted to new segmentation

Benign large loss experience in 1H/2014

Catastrophe losses* in m. EUR	Date	Gross	Net
Snowstorm, Japan	8 Feb	10.5	8.9
Storm "Ela", France/Belgium/Germany	7 - 10 Jun	39.2	33.3
2 Natural catastrophes		49.7	42.2
1 Aviation claim		51.5	30.9
3 Property claims		42.3	31.6
6 Major losses		143.5	104.7

^{*} Natural catastrophes and other major losses in excess of EUR 10 m. gross

Significantly improved result in life and health reinsurance

Life and health R/I in m. EUR	Q2/2013	Q2/2014	1H/2013	1H2014	YTD
Gross written premium	1,569	1,470	3,130	2,987	► GWP f/x-adjusted -1.8%, mainly due to reduced premium income from enhanced annuities biz,
Net premium earned	1,398	1,188	2,787	2,469	single large transactions, run-off of US mortality block (ING); increased volume from UK-BAT
Net underwriting result incl. funds withheld	(10)	22	14	22	► Technical result increased largely due to improved result from US mortality business
Net investment income from assets under own management	64	67	136	134	 NII at expected level, minor impact from ModCo derivatives
Other income and expenses	(22)	0	(16)	(1)	 Other income improved mainly due to reduced collateral costs for our US business
Operating profit/loss (EBIT)	31	89	134	155	➤ Strong increase in EBIT by 16%
EBIT margin	2.2%	7.5%	4.8%	6.3%	► EBIT margins well above targets: Financial solutions/longevity business: 4.8%
Tax ratio	18.6%	18.3%	24.4%	18.8%	Mortality and morbidity business: 7.1%
Group net income	25	72	100	115	
Earnings per share	0.20	0.60	0.83	0.96	



Stable ordinary investment income as expected

Rol on track towards 2014 target of 3.2%

in m. EUR	Q2/2013	Q2/2014	1H/2013	1H/2014	Rol
Ordinary investment income*	263	250	510	494	3.1%
Realised gains/losses	50	34	84	88	0.6%
Impairments/appreciations & depreciations	(5)	(5)	(8)	(10)	-0.1%
Change in fair value of financial instruments (through P&L)	(41)	3	(38)	10	0.1%
Investment expenses	(26)	(22)	(47)	(50)	-0.3%
NII from assets under own mgmt.	240	260	501	533	3.3%
NII from funds withheld	94	86	188	175	
Total net investment income	334	346	689	708	

Change in fair value of financial instruments	31 Dec 13	30 Jun 14
Fixed income (AFS)	426	931
Fixed income (HTM, L&R)	342	434
Equities and shares in limited partnerships	284	338
Total	1,052	1,703

^{*} Incl. results from associated companies

YTD

- Ordinary income almost on 1H/2013 level while average portfolio volume remained stable
- ▶ Realisations on previous year's level
- ► Increase in regular depreciations due to higher real estate volume
- Normalisation of unrealised result in P/L leads to increase in NII
- Valuation reserves recovered due to lower yield levels of European governments and tighter spreads on US corporates



Target Matrix 2014

Most targets achieved

Business group	Key figures	Strategic targets	1H/2014
Group	Return on investment ¹⁾	≥3.2%	3.3%
	Return on equity	≥9.6% ²⁾	14.5%
	Earnings per share growth (y-o-y)	≥10%	4.9%
	Value creation per share ³⁾	≥10%	n.a.
Non-life reinsurance	Gross premium growth ⁴⁾	3% - 5%	2.0%
	Combined ratio	≤96% ⁵⁾	95.0%
	EBIT margin ⁶⁾	≥10%	15.5%
	xRoCA ⁷⁾	≥2%	n.a.
Life and health reinsurance	Gross premium growth ⁸⁾	5% - 7%	-1.8%
	Value of New Business (VNB)	≥EUR 180 m.	n.a.
	EBIT margin ⁶⁾ financial solutions/longevity business	≥2%	4.8%
	EBIT margin ⁶⁾ mortality and morbidity business	≥6%	7.1%
	xRoCA ⁷⁾	≥3%	n.a.

¹⁾ Excl. inflation swaps and ModCo



³⁾ Growth of book value + paid dividend

⁵⁾ Incl. expected net major losses of EUR 670 m.

⁷⁾ Excess return on the allocated economic capital

^{2) 750} bps above 5-year rolling average of 10-year German government-bond rate ("risk free"), after tax

⁴⁾ In average throughout the cycle; at unchanged f/x rates


⁶⁾ EBIT/net premium earned

⁸⁾ Organic growth only; at unchanged f/x rates; 5-year CAGR

Q2/2014 renewals

renewals

17% of our non-life traditional treaty biz was up for renewal in Q2 Renewals 2014



renewals

hannover **re**®


renewals

renewal

Based on 2013 U/Y

Premium reduced by 13% as we discontinued marginal business

We continued to strictly adhere to our selective underwriting approach



At unchanged f/x rates



Outlook 2014

Guidance for 2014

Major loss budget of EUR 670 m.

Hannover Re Group

- ► Gross written premium¹⁾ _____ flat to low single-digit increase in volume
- ► Return on investment²⁾ _____~ 3.2%
- ► Group net income³⁾ _____ ~ EUR 850 m.

¹⁾ At unchanged f/x rates

²⁾ Excluding effects from derivatives (ModCo/inflation swaps)

³⁾ Subject to no major distortions in capital markets and/or major losses in 2014 not exceeding approx. EUR 670 m.

⁴⁾ Related to group net income according to IFRS

Overall largely stable portfolio with continued good quality

Development of non-life reinsurance lines of business (FY 2014e)

_	Lines of business	Volume ¹⁾	Profitability ²⁾
Target	North America ³⁾	2	+
markets	Germany ³⁾	(3)	+
	Marine (incl. energy)		+
	Aviation	$igoreal{igoreal}$	-
Specialty lines	Credit, surety & political risks	S	+
	Structured R/I & ILS	2	+/-
	UK, London market & direct	S	+/-
	Worldwide treaty ³⁾		+
Global R/I	Global cat XL	S	+
	Facultative	2	+/-

¹⁾ Premium development in EUR at unchanged f/x rates

^{2) ++ =} well above CoC; +/ = above CoC; +/- = CoC earned; - = below Cost of Capital (CoC)

³⁾ All lines of business except those stated separately

Life and health R/I profitability back on track in 2014

Positive contributions from all reporting categories

_	Reporting categories	Volume ¹⁾	Profitability ²⁾
Financial Solutions	Financial Solutions		++
	Longevity	2	+
Risk Solutions	Mortality		+
	Morbidity	ightharpoonup	+/-

¹⁾ Premium development in EUR at unchanged f/x rates

^{2) ++ =} well above CoC; + = above CoC; +/- = CoC earned; - = below Cost of Capital (CoC)

Appendix

Our strategic business groups at a glance

1H/2014 vs. 1H/2013

		Non-life reinsurance		Life and health reinsurance		Total	
in m. EUR	1H/2013	1H/2014	1H/2013	1H/2014	1H/2013	1H/2014	
Gross written premium	4,097	4,078	3,130	2,987	7,227	7,065	
Change in GWP	-	-0.5%	-	-4.6%	-	-2.2%	
Net premium earned	3,404	3,370	2,787	2,469	6,192	5,839	
Net underwriting result	184	158	(166)	(144)	17	14	
Net underwriting result incl. funds withheld	191	168	14	22	204	189	
Net investment income	363	399	316	300	689	708	
From assets under own management	355	389	136	134	501	533	
From funds withheld	8	9	180	165	188	175	
Other income and expenses	2	(36)	(16)	(1)	(13)	(38)	
Operating profit/loss (EBIT)	549	521	134	155	693	684	
Interest on hybrid capital	(0)	0	0	(0)	(63)	(49)	
Net income before taxes	549	521	134	155	630	635	
Taxes	(154)	(148)	(33)	(29)	(172)	(156)	
Net income	395	372	101	126	458	479	
Non-controlling interest	33	25	2	10	35	35	
Group net income	362	348	100	115	423	444	
Retention	90.2%	91.1%	89.6%	83.1%	90.0%	87.7%	
Combined ratio (incl. interest on funds withheld)	94.4%	95.0%	99.5%	99.1%	96.7%	96.8%	
EBIT margin (EBIT / Net premium earned)	16.1%	15.5%	4.8%	6.3%	11.2%	11.7%	
Tax ratio	28.0%	28.5%	24.4%	18.8%	27.3%	24.5%	
Earnings per share	3.00	2.89	0.83	0.96	3.51	3.69	



Our strategic business groups at a glance

Q2 stand-alone

	Non-life reinsurance		Life and health reinsurance		Total	
in m. EUR	Q2/2013	Q2/2014	Q2/2013	Q2/2014	Q2/2013	Q2/2014
Gross written premium	1,899	1,970	1,569	1,470	3,469	3,440
Change in GWP	-	+3.7%	-	-6.3%	-	-0.8%
Net premium earned	1,712	1,739	1,398	1,188	3,111	2,927
Net underwriting result	 85	71	(100)	(59)	(15)	12
Net underwriting result incl. funds withheld	90	76	(10)	22	79	98
Net investment income	176	194	153	148	334	346
From assets under own management	172	188	64	67	241	260
From funds withheld	4	6	89	81	94	86
Other income and expenses	29	(24)	(22)	0	7	(24)
Operating profit/loss (EBIT)	290	241	31	89	327	334
Interest on hybrid capital	(0)	0	0	(0)	(32)	(21)
Net income before taxes	290	241	31	89	295	313
Taxes	(87)	(83)	(6)	(16)	(85)	(93)
Net income	203	157	26	73	209	220
Non-controlling interest	16	7	1	1	17	8
Group net income	187	150	25	72	192	211
Retention	90.8%	91.1%	89.3%	81.7%	90.1%	87.1%
Combined ratio (incl. interest on funds withheld)	94.8%	95.6%	100.7%	98.1%	97.5%	96.6%
EBIT margin (EBIT / Net premium earned)	17.0%	13.8%	2.2%	7.5%	10.5%	11.4%
Tax ratio	30.0%	34.6%	18.6%	18.3%	29.0%	29.8%
Earnings per share	1.55	1.24	0.20	0.60	1.59	1.75



Asset allocation unchanged

Rise in assets under management despite EUR 750 m. bond redemption in Feb.

Tactical asset allocation¹⁾

Investment category	2010	2011	2012	2013	1H/2014
Fixed-income securities	84%	89%	91%	89%	89%
- Governments	23%	19%	19%	19%	20%
- Semi-governments	21%	23%	23%	20%	20%
- Corporates	25%	30%	32%	34%	35%
Investment grade	24%	29%	30%	33%	33%
Non-investment grade	1%	1%	2%	2%	2%
- Pfandbriefe, Covered Bonds, ABS	16%	16%	17%	15%	15% ²⁾
Equities	4%	2%	2%	2%	2%
- Listed	2%	<1%	<1%	<1%	<1%
- Private Equity	2%	2%	2%	2%	2%
Real estate/real estate funds	2%	2%	2%	4%	4%
Others	2%	2%	2%	2%	2%
Short-term investments & cash	8%	5%	3%	4%	4%
Total balance sheet values in bn. EUR	25.4	28.3	31.9	31.9	32.4

¹⁾ Economic view based on market values without outstanding commitments for Private Equity and Alternative Real Estate as well as fixed-income investments of EUR 618.0 m. (EUR 598.5 m.) as at 30 June 2014



²⁾ Of which Pfandbriefe and Covered Bonds = 82.4%

Stress tests on assets under own management

Unchanged focus on the credit portfolio

Portfolio	Scenario	Change in market value in m. EUR	Changes in OCI before tax in m. EUR
Equity (Listed and Private Equity)	-10%	-64	-64
	-20%	-128	-128
Yield curves	+50 bps	-643	-529
	+100 bps	-1,267	-1,034
Credit spreads	+50%	-587	-545

Fixed-income book well balanced

Allocation reflects reinsurance liabilities


	Governments	Semi- governments	Corporates	Pfandbriefe, Covered Bonds, ABS	Short-term investments, cash	Total
AAA	66.1%	53.6%	1.6%	61.7%	-	37.1%
AA	17.4%	43.7%	16.7%	14.4%	-	22.3%
A	9.8%	1.3%	49.0%	13.3%	-	24.1%
BBB	5.5%	0.9%	26.4%	5.7%	-	12.8%
<bbb< td=""><td>1.2%</td><td>0.5%</td><td>6.3%</td><td>4.9%</td><td>-</td><td>3.7%</td></bbb<>	1.2%	0.5%	6.3%	4.9%	-	3.7%
Total	100.0%	100.0%	100.0%	100.0%	-	100.0%
Germany	8.8%	41.8%	5.1%	24.9%	26.0%	17.4%
UK	8.1%	2.8%	8.6%	9.7%	7.8%	7.4%
France	5.7%	3.0%	6.3%	6.9%	1.0%	5.4%
GIIPS	2.6%	0.5%	3.6%	7.9%	0.0%	3.2%
Rest of Europe	10.6%	23.6%	18.7%	30.9%	4.3%	19.3%
USA	45.3%	8.7%	35.3%	4.5%	12.7%	26.3%
Australia	3.9%	7.3%	8.7%	9.0%	14.9%	7.7%
Asia	9.1%	2.8%	4.7%	0.0%	23.7%	5.3%
Rest of World	5.9%	9.5%	9.0%	6.2%	9.6%	8.0%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total b/s values in bn. EUR	6,499	6,194	11,328	4,602	1,182	29,805

As at 30 June 2014

Currency allocation matches liability profile of balance sheet

Active asset liability management ensures durational match

Currency split of investments



- Modified duration of fixed income mainly congruent with liabilities
- GBP's higher modified duration predominantly due to life business

Modified duration

2013	4.4
2012	4.5
2011	4.2

Modified duration as at 30 June 2014: 4.4 (31 December 2013: 4.4)



Inflation hedges

Positive contribution at mid-year

- Average hedged inflation level of 2.04% EUR and 2.48% USD p.a.
 - P&L effect YTD EUR +4.5 m. (thereof EUR -5.2 m.; +9,7 m. EUR of USD)
 - OCI effect YTD EUR +2.4 m. (thereof EUR -3.1 m.; +5.5 m. EUR of USD)
- ▶ Instruments held as inflation hedges (30 June 2014) with volume of EUR 2,326 m.
 - EUR 1,740 m. swap volume with average duration of 1.5 years
 - EUR 586 m. volume of inflation linker with average duration of 4.8 years
- Sensitivity to inflation risk:

in m. EUR	Inflation Swaps: Change in market value through P/L	Inflation Linked Bonds: Change in market value through OCI	Total economic inflation effect before taxes
Inflation expectation*: +100 BP	26	29	55
Inflation expectation*: -100 BP	-26	-28	-54
Inflation expectation*: +400 BP	108	124	232

^{*} CPI - Consumer Price Index (US inflation index)



HICP - Harmonised Indices of Consumer Prices (EU inflation index; actually traded is the sub-index HICP ex tobacco)

Disclaimer

This presentation does not address the investment objectives or financial situation of any particular person or legal entity. Investors should seek independent professional advice and perform their own analysis regarding the appropriateness of investing in any of our securities.

While Hannover Re has endeavoured to include in this presentation information it believes to be reliable, complete and up-to-date, the company does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such information.

Some of the statements in this presentation may be forward-looking statements or statements of future expectations based on currently available information. Such statements naturally are subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements.

This presentation serves information purposes only and does not constitute or form part of an offer or solicitation to acquire, subscribe to or dispose of, any of the securities of Hannover Re.

© Hannover Rück SE. All rights reserved. Hannover Re is the registered service mark of Hannover Rück SE.